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Introduction
Hepatitis B virus (HBV) infection is a major health problem
leading to significant morbidity and mortality. An
estimated 400 million global population is chronically
infected.1 Most carriers of chronic HBV are from Asian,
African and Mediterranean countries where perinatal
transmission of the disease is high.2 These chronic
infections are responsible for around 40% of
hepatocellular carcinomas in endemic regions.3 Pakistan
currently falls in the intermediate HBV prevalence group.4
In 2003, Pakistan Society of Gastroenterology issued a
consensus statement on prevalence of HBV, according to
which there are an estimated 4.5 million carriers in
Pakistan with a carrier rate of 3-4%.4 A more recently
published meta analysis has revealed an overall HBsAg
seroprevalence in healthy adults to be 2.4%.5
In 2002-03, HBV vaccination was introduced in the
national Expanded Programme on Immunisation (EPI);
attention was given to children under 1 year of age.6
Impact of vaccination on our population has not been
reported as yet. Thus, there is a dire need for studies that
can show the disease in burden and to classify the
affected population into clinically relevant groups such as
susceptible, acute/chronic infection versus immunised
group. Findings of such studies will help the policymakers
in directing their limited resources effectively.
In the current study, we analysed a large data set of HBV
serology performed over a period of 8 years. Main
objectives were to analyse the trends of HBV serological
markers and classify serological picture into clinically
relevant groups, according to internationally recognised
Centre for Disease Control (CDC) classification.7 This is the
first study from Pakistan that has attempted to assess
trend of disease in various geographical regions and
classify patients into different clinical groups.
Materials and Methods
The retrospective analysis of HBV serology involved
samples from 2001 to 2008 at the Aga Khan University
Hospital (AKUH), a 591-bed tertiary care centre located in
Karachi, Pakistan. During the study period 185,825
patients had serological markers for hepatitis B tested.
Data was analysed during the year 2009. The clinical
laboratory of AKUH has a network of sample collection
centres located in 50 major cities and towns of Pakistan.
This extensive networking makes the laboratory data
representative of the country; hence disease burden was
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Abstract
Objective: To study the changing trends of hepatitis B  markers tested at Aga Khan University Hospital  clinical
laboratory according to the internationally recognised classification of hepatitis B  profile.
Methods: The retrospective study involved analysis of laboratory records of hepatitis B  profiles of all patients
collected from January 2001 to December 2008 at the Aga Khan University Hospital's clinical laboratory. Patients
with complete profile tested were categorised according to the Centre for Diseases Control classification of hepatitis
B profile. SPSS 16 was used for statistical analysis.
Results: A total of 185,825 patients had serological markers for hepatitis B tested. Mean-age of reactive hepatitis B
surface antigen (HBsAg) patients was 30±12.5 years. HBsAg reactivity was significantly higher in males than females
(34% vs 12%; p <0.0001). HBsAg showed a slight decline in the percentage reactivity during the 8-year study period,
while a gradual increase in hepatitis B surface antibody (HBsAb) reactivity was observed. Of the total, 23% patients
belonged to the 'susceptible to infection' category; 39% patients were classified as 'chronically-ill'; 12% patients
were categorised as 'immune due to hepatitis B  vaccination'. 3% patients were classed as 'acutely infected'. Overall,
samples received from Peshawar, Quetta and Larkana showed very high reactivity rates.
Conclusion: The study substantiated the general perception that levels of HBsAg is showing a decreasing trend,
while levels of HBsAb are increasing perhaps due to better vaccination of population.
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also analysed based on geographical locations within the
country.
Classification was performed on patients that had all
hepatitis B markers tested. They were categorized,
according to CDC criteria, into 6 groups based on their
serological profile:8
Group-1 (susceptible): HBsAg, hepatitis B core antibody
(HBcAb; IgG) and HBsAb negative;
Group-2 (immune due to natural infection): HBsAg
negative and HBcAb (IgG) and HBsAb were positive; 
Group-3 (immune due to hepatitis B vaccination): HBsAg,
HBcAb (IgG) were found negative with positive HBsAb; 
Group-4 (acute infection): HBsAg, HBcAb (IgM) and HBcAb
(IgG) positive along with negative HBsAb; 
Group-5 (chronic infection): HBsAg and HBcAb (IgG)
positive along with negative HBcAb (IgM) and HBsAb; 
Group-6 (possibility of multiple interpretations): HBsAg
and HBsAb negative along with HBcAb (IgG) positive
results — may be recovering from acute HBV infection or
may be distantly immune and test not sensitive enough
to detect very low level of HBsAb in serum or may be
undetectable level of HBsAg present in the serum and the
person is actually chronically infected or/and may be
susceptible with a false positive HBcAb (IgG).
All data was entered into SPSS 16.0. Frequencies were
generated for categorical variables, and mean with
standard deviation for continuous variables. Cross-
tabulation was done to determine relationship between
different groups.
Results
A total of 396,348 patients were tested for HBsAg during
the study period. Of these, 85215 (21.5%) tested positive
by microparticle enzyme immunosorbent assay (MEIA)
method. Mean age of population reactive to HBsAg was
29.8±12.5 years (Figure-1). Overall, 66261 (30%) males
were reactive for HBsAg, while 18954 (11%) females were
found reactive for this marker. Mean ages for males and
females positive for HBsAg were comparable (30.0±12.4
vs 29.8±13.0 years). In the study population, 19236 (5%)
were patients under 10 years of age. Majority 31955
(37.5%) of positive samples belonged to the 20-30 age
group. Analysis of overall data showed progressive
decline in percent positivity for HBsAg. It declined from
24% in 2001 to 18% in 2008 (Figure-2).
When analysed according to geographical location of
sample collection site, the frequency of HBsAg positivity
was lower for samples received from larger cities of
Pakistan (15-21%), while it was relatively high for samples
received from smaller cities (43-55%).
Besides, 69,331 patients were tested for hepatitis B 'E'
antigen (HBeAg). Of them, 13381 (19.3%) were found
reactive, with the majority (31%; n=4148) belonging to
the 20-30 age group. Mean age and male-to-female ratio
for positive serum samples was 25.0±14.0 years, 1.1
respectively. Overall, percentage of population reactive
for this marker marginally decreased from 19% in 2001 to
18% in 2008.
As for HBsAb 58,549 patients were tested. Of these, 29626
(50.6%) were found reactive; 40% (n=11850) of the positive
samples were received from the 20-30 age group. A gradual
increase in frequency of patients reactive for HBsAb was
noted; it increased from 47% in 2001 to 52% in 2008.
In terms of HBcIgG, 21098 patients were tested and 12448
(59%) were positive. The number of reactive patients
remained steady during the study period; and the 20-30
age group provided the bulk of the positive samples
(30%; n=3734).
With respect to HBeAb, 31,395 patients were tested, of
whom 19779 (63%) were reactive, and 34% (n=6724)
being from the 20-30 age group. There was an increase in
the level of this marker from 57% in 2001 to 63% in 2008.
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Table: Classification of hepatitis B profiles.
CDC Category 2001 2002 2003 2004 2005 2006 2007 2008 Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Susceptible 377 (27) 230 (26) 142 (22) 241 (21) 233 (24) 328 (25) 189 (22) 288 (23) 2028 (24)
Immune due to natural infection 156 (11) 67 (8) 54 (8) 95 (8) 81 (8) 97 (7) 71 (8) 123 (10) 744 (8.5)
Immune due to hepatitis B vaccination 143 (10) 98 (11) 76 (12) 114 (10) 123 (12) 180 (14) 68 (8) 220 (18) 1022 (12)
Acutely infected 42 (3) 28 (3) 14 (2) 33 (3) 24 (2) 24 (2) 25 (3) 20 (2) 210 (2.5)
Chronic infected 582 (42) 394 (45) 311 (48) 583 (50) 456 (46) 607 (46) 455 (54) 549 (44) 3937 (46.5)
Multiple Interpretations possible 78 (6) 36 (4) 38 (6) 64 (6) 57 (6) 63 (5) 37 (4) 34 (3) 407 (5)
Unclassifiable 22 (2) 24 (3) 10 (2) 29 (3) 17 (2) 12 (1) 5 (1) 4 (0) 123 (1.5)
Total 1400 877 645 1159 991 1311 850 1238 4390
Complete hepatitis B  profile was done on 4390 patients
and were further analysed for clinical classification
according to the CDC criteria.7 Of the total, 1038 (24%)
patients were classified as 'susceptible to infection'; 8%
(372) patients were classified as 'immune due to natural
infection' 591 (13%) were 'immune due to vaccination'; 93
(2%) and 2067 (47%) showed profile suggestive of 'acute'
and 'chronic' infection respectively; 191 (4%) were classified
as having multiple interpretations of their profiles; and 44
(1%) cases on an average could not be classed into any
category and were labeled as unclassified (Table).
Discussion
The study showed that HBV infection is a disease of
children and young adults in Pakistan with maximum
disease acquisition in the first to third decades.
Throughout the study period, maximum number of
specimens submitted to the laboratory were from these
age groups and were found positive for various
seromarkers. Early exposure is of great concern as
childhood acquisition of disease results in higher
morbidity and mortality and is a major burden to a
poorly-funded healthcare system of a developing
country. Poverty and prevailing lower socioeconomic
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Figure-1: Cumulative graph showing age distribution of patients reactive for different hepatitis B seromarkers.
Figure-2: Year-wise trends of HBsAg, HBsAb, HBeAg, HBcAb (IgG) and HBeAb in
patients tested from 2001 to 2008.
conditions along with inadequate healthcare facilities are
known factors in the dissemination of HBV infection in
early childhood. As per published reports, Pakistan is
amongst those countries where reuse of syringes for
therapeutic purposes and intravenous (IV) medications is
highly prevalent.9,10 Use of inadequately disinfected and
unsterilised equipment in majority of the healthcare
facilities is another major issue playing role in disease
dissemination.11,12 These factors have also been
implicated as a major cause of disease transmission in our
neighbouring countries which bear similar burden of HBV
infections.2,13,14 In contrast to the findings of our study,
reports from Taiwan and China have quoted vertical
transmission in neonates as the main cause of childhood
acquisition of disease.15,16 Similarly, surveillance data
published from the developed world show sexual
(homosexual, heterosexual, multiple partners) and IV
drug addiction as the main mode of disease transmission.
This is also reflected by the fact that major disease burden
in these countries is among older age groups, that is in the
third and fourth decades of life.8,17
Our data demonstrates that seroprevalence is three-fold
higher amongst the male population. Previously
published community data from this region also shows
higher seroprevalence of HBV among males, but not at
this scale.18 Circumcision in early childhood, regular
barber shop visits and higher rates of IV drug addiction
are major risk factors which places males more exposed to
blood-borne infections. Additionally, greater excess to
health care facilities and IV medications further exposes
them to such diseases and diagnosis.8-11,19,20
In countries with high seroprevalence of HBV infection,
such as Thailand and Taiwan, vaccination programme was
launched in the 1980s. Multiple long-term followup
reports from these countries are showing dramatic change
in its acquisition and epidemiology.21,22 In Pakistan,
vaccination was included in the EPI in 2002-03.6 In our
study, it was noted that during the second half, that is from
2005-2008, a rise in HBsAb and fall in HBsAg and HBeAg
occurred. Recently, similar findings were reported in the
national prevalence survey of Hepatitis B and C conducted
by the Pakistan Medical Research Council.23 This may
reflect results of vaccination among infants and children
and may also be a direct result of the increased trend of
immunisation in the general population due to their better
understanding and awareness of the disease through
electronic media and governmental campaigns, especially
in urban regions of Pakistan. This finding is further
endorsed by the application of CDC classification, which
also shows that in the later part of the study period, there
is a rising trend in the vaccinated group, fall in acutely
infected population and susceptible population. This trend
is encouraging and indicates that a comprehensive
hepatitis control programme focused on improved
awareness and easy availability of vaccines can possibly
reduce disease transmission and burden in endemic
regions of the country.
Another interesting finding of this study was a high
number of positive serum samples received from the
central region of Pakistan which comprises southern
Punjab, northern Sind and parts of Balochistan. This region
is also known for high prevalence of hepatitis D and
human immunodeficiency virus (HIV) infections.24,25 These
findings indicate that blood and body fluid borne disease
transmission is perhaps occurring consistently and
causing micro-epidemics in various regions of Pakistan.
These regions are in dire need of preventive strategies
such as immunisations and improvements in healthcare
units. Implementation of infection control in all health
centres, mass education on the use of syringes and to
avoid unnecessary injections might also prove useful.
The strength of our study was its good sample size and
the findings report decreasing trend of disease
acquisition in local population for the first time in
Pakistan. However, there are certain limitations and
inherited weaknesses of the study. Firstly, it is a
retrospective evaluation of laboratory data; secondly, we
were not able to randomise the included population; and
the data includes healthy people tested for reasons other
then being diseased, that is, jobs, travel etc.
Conclusion
Acquisition of HBV infection seems to be occurring at an
early age with wide variation in its prevalence in different
geographical regions within Pakistan. There is a decreasing
trend of disease transmission, but for its further effective
control the federal government, the World Health
Organisation and other funding agencies need to work in
collaboration. EPI needs to be strengthened across the
country and policy of mandatory vaccination to all should
be adopted in areas with very high prevalence of disease.
Further, countrywide community-based surveys are
required to validate these trends and assess the true
effects of immunisation in our population.
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